TargetBeta
CD22
CD22 molecule · also SIGLEC-2, SIGLEC2 · CD molecules
2 programs in company-led studies act on CD22, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Anti-CD22/Topoisomerase I Inhibitor Antibody-drug Conjugate AZD4512 | AstraZeneca | phase 2 | 22 running | – | a judged reading |
| REGN9220rule | Regeneron Pharmaceuticals | phase 2 | 11 running | CD3E, MS4A1 | the studies' text |
Conditions their studies are in
- Burkitt Lymphoma, 1 program
- Lymphoma, B-Cell, 1 program
- Lymphoma, Large B-Cell, Diffuse, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jul 4, 2028Anti-CD22/Topoisomerase I Inhibitor Antibody-drug Conjugate AZD4512 · AstraZeneca · phase 2 · NCT07123454
- Nov 1, 2029REGN9220 · Regeneron Pharmaceuticals · phase 2 · NCT07887750
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.